Double Medical Technology Inc
Double Medical Technology Inc. engages in the research, development, production, sale, and high-value medical consumables in China. The company provides products for orthopedics, minimally invasive surgery, neurosurgery, wound surgery, and dentistry, etc. It also exports its products to various countries and regions. The company was formerly known as Xiamen Da Bo Ying Jing Medical Equipment Compa… Read more
Double Medical Technology Inc (002901) - Net Assets
Latest net assets as of September 2025: CN¥3.44 Billion CNY
Based on the latest financial reports, Double Medical Technology Inc (002901) has net assets worth CN¥3.44 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.55 Billion) and total liabilities (CN¥1.12 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.44 Billion |
| % of Total Assets | 75.47% |
| Annual Growth Rate | 27.25% |
| 5-Year Change | 49.1% |
| 10-Year Change | 620.17% |
| Growth Volatility | 30.37 |
Double Medical Technology Inc - Net Assets Trend (2013–2024)
This chart illustrates how Double Medical Technology Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Double Medical Technology Inc (2013–2024)
The table below shows the annual net assets of Double Medical Technology Inc from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.18 Billion | +0.66% |
| 2023-12-31 | CN¥3.16 Billion | +1.73% |
| 2022-12-31 | CN¥3.11 Billion | +20.03% |
| 2021-12-31 | CN¥2.59 Billion | +21.30% |
| 2020-12-31 | CN¥2.13 Billion | +21.70% |
| 2019-12-31 | CN¥1.75 Billion | +20.28% |
| 2018-12-31 | CN¥1.46 Billion | +17.71% |
| 2017-12-31 | CN¥1.24 Billion | +113.49% |
| 2016-12-31 | CN¥580.13 Million | +31.31% |
| 2015-12-31 | CN¥441.78 Million | +61.03% |
| 2014-12-31 | CN¥274.36 Million | +22.15% |
| 2013-12-31 | CN¥224.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Double Medical Technology Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 784.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.53 Billion | 49.66% |
| Common Stock | CN¥414.02 Million | 13.45% |
| Other Comprehensive Income | CN¥408.42 Million | 13.26% |
| Other Components | CN¥727.40 Million | 23.62% |
| Total Equity | CN¥3.08 Billion | 100.00% |
Double Medical Technology Inc Competitors by Market Cap
The table below lists competitors of Double Medical Technology Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dream Finders Homes Inc
NYSE:DFH
|
$399.09 Million |
|
Hangzhou Huawang New Material Technology Co.Ltd.
SHG:605377
|
$399.10 Million |
|
Hinova Pharmaceuticals Inc. A
SHG:688302
|
$399.12 Million |
|
ARROW FINL CORP. DL 1
F:BQE
|
$399.39 Million |
|
Fitipower Integrated Technology Inc
TW:4961
|
$399.04 Million |
|
Vitesco Technologies Group Aktiengesellschaft
PINK:VTSCY
|
$398.84 Million |
|
Kunshan Top A Intelligent Equipment
SHE:300836
|
$398.83 Million |
|
JAPAN AVIATION EL.
F:8N9
|
$398.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Double Medical Technology Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,058,492,000 to 3,078,989,000, a change of 20,497,000 (0.7%).
- Net income of 356,803,432 contributed positively to equity growth.
- Dividend payments of 118,068,000 reduced retained earnings.
- Share repurchases of 234,979,899 reduced equity.
- Other comprehensive income increased equity by 408,423,700.
- Other factors decreased equity by 391,682,233.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥356.80 Million | +11.59% |
| Dividends Paid | CN¥118.07 Million | -3.83% |
| Share Repurchases | CN¥234.98 Million | -7.63% |
| Other Comprehensive Income | CN¥408.42 Million | +13.26% |
| Other Changes | CN¥-391.68 Million | -12.72% |
| Total Change | CN¥- | 0.67% |
Book Value vs Market Value Analysis
This analysis compares Double Medical Technology Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.97x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 63.15x to 5.97x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥0.70 | CN¥44.30 | x |
| 2014-12-31 | CN¥0.68 | CN¥44.30 | x |
| 2015-12-31 | CN¥1.37 | CN¥44.30 | x |
| 2016-12-31 | CN¥1.60 | CN¥44.30 | x |
| 2017-12-31 | CN¥3.32 | CN¥44.30 | x |
| 2018-12-31 | CN¥3.61 | CN¥44.30 | x |
| 2019-12-31 | CN¥4.30 | CN¥44.30 | x |
| 2020-12-31 | CN¥5.26 | CN¥44.30 | x |
| 2021-12-31 | CN¥6.23 | CN¥44.30 | x |
| 2022-12-31 | CN¥7.25 | CN¥44.30 | x |
| 2023-12-31 | CN¥7.26 | CN¥44.30 | x |
| 2024-12-31 | CN¥7.42 | CN¥44.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Double Medical Technology Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.59%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.71%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 1.44x
- Recent ROE (11.59%) is below the historical average (27.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 43.20% | 47.77% | 0.68x | 1.32x | CN¥74.40 Million |
| 2014 | 51.35% | 46.60% | 0.55x | 2.01x | CN¥112.17 Million |
| 2015 | 42.97% | 48.15% | 0.70x | 1.28x | CN¥144.76 Million |
| 2016 | 38.22% | 47.41% | 0.64x | 1.25x | CN¥161.94 Million |
| 2017 | 24.08% | 49.76% | 0.43x | 1.13x | CN¥172.83 Million |
| 2018 | 25.80% | 48.09% | 0.46x | 1.16x | CN¥227.46 Million |
| 2019 | 27.03% | 37.02% | 0.56x | 1.30x | CN¥293.31 Million |
| 2020 | 28.79% | 38.17% | 0.60x | 1.25x | CN¥395.29 Million |
| 2021 | 26.80% | 33.76% | 0.59x | 1.35x | CN¥422.06 Million |
| 2022 | 3.09% | 6.45% | 0.36x | 1.31x | CN¥-207.46 Million |
| 2023 | 1.93% | 3.85% | 0.33x | 1.52x | CN¥-246.89 Million |
| 2024 | 11.59% | 16.71% | 0.48x | 1.44x | CN¥48.90 Million |
Industry Comparison
This section compares Double Medical Technology Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $3,466,050,746
- Average return on equity (ROE) among peers: 18.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Double Medical Technology Inc (002901) | CN¥3.44 Billion | 43.20% | 0.33x | $399.08 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $398.02 Million | 18.74% | 0.22x | $325.38 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $7.49 Billion | 23.47% | 0.34x | $2.80 Billion |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $2.85 Billion | 49.59% | 0.20x | $288.07 Million |
| Lepu Medical Tech Beijing (300003) | $16.74 Billion | 1.48% | 0.47x | $2.77 Billion |
| INKON Life Technology Co Ltd (300143) | $116.90 Million | 17.41% | 0.92x | $621.57 Million |
| Edan Instruments Inc (300206) | $1.25 Billion | 3.50% | 0.14x | $527.51 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $1.29 Billion | -5.53% | 0.94x | $377.92 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $105.32 Million | 39.32% | 0.45x | $271.42 Million |
| Sinocare Inc (300298) | $946.01 Million | 17.47% | 0.11x | $954.87 Million |